Merck & Co., Inc. (NYSE:MRK) EVP Jennifer Zachary Sells 80,315 Shares

Key Points

• Insider selling: Merck EVP Jennifer Zachary sold 80,315 shares for approximately $10.7 million at an average price of $133.46, reducing her stake by 63.83% to 45,509 shares.
• Solid operating performance: Merck reported quarterly revenue of $16.61 billion, exceeding estimates, with revenue up 5.1% year over year. Shares traded near their 52-week high at $135.57, while analysts maintained a “Moderate Buy” consensus and a $135.50 average price target.
• Shareholder returns and risks: The company declared a quarterly dividend of $0.85 per share, equivalent to a 2.5% annual yield. Analysts continue to cite Keytruda’s patent expiration and concentration in the drug as important longer-term risks, increasing the importance of Merck’s pipeline diversification.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Merck & Co., Inc. Price Performance

MRK stock traded up $2.65 during trading on Thursday, hitting $135.57. The company had a trading volume of 8,875,510 shares, compared to its average volume of 10,698,729. The company has a fifty day moving average price of $124.94 and a two-hundred day moving average price of $119.64. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.68. The company has a market cap of $334.49 billion, a P/E ratio of 108.46, a P/E/G ratio of 5.62 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support the shares: Daiwa Securities raised Merck to “outperform” with a $143 price target, while Argus maintained a “buy” rating and lifted its target to $145. These actions reinforce the view that Merck’s recent momentum can continue. Merck analyst price target article
• Positive Sentiment: Keytruda and the core business remain strong: Merck’s second-quarter growth was driven primarily by Keytruda demand in early-stage and metastatic cancers, oncology products, new launches and Animal Health. Quarterly revenue of $16.61 billion exceeded the $16.37 billion consensus estimate, and revenue increased 5.1% year over year. Merck second-quarter earnings call article
• Positive Sentiment: Pipeline diversification is advancing: The FDA and European Medicines Agency accepted applications for broader ENFLONSIA use to prevent RSV in vulnerable young children. Expanded approval could create an additional growth avenue beyond oncology as Keytruda approaches eventual patent expiration. Merck ENFLONSIA RSV regulatory review article
• Neutral Sentiment: Earnings expectations are stable to slightly improved: Erste Group raised its FY2026 EPS estimate to $2.75 from $2.70, close to the roughly $2.77 consensus. Merck also declared its regular $0.85 quarterly dividend, or $3.40 annualized.
• Negative Sentiment: Keytruda concentration remains the main risk: Analysts caution that patent loss and increasing competition could eventually slow the drug’s sales growth, making the company’s pipeline and newer products increasingly important. Keytruda growth outlook article
• Negative Sentiment: Recent insider selling may temper sentiment: EVP Richard Deluca disclosed sales totaling more than 45,000 shares across transactions from August 10–12, while retaining a substantial position. The sales are not necessarily a fundamental signal, but could modestly weigh on investor confidence.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in the stock. Osbon Capital Management LLC bought a new position in shares of Merck & Co., Inc. in the second quarter worth about $279,000. LM Advisors LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $1,814,000. TrinityBridge Ltd bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $446,000. Jupiter Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $1,773,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $969,000. Institutional investors own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MRK shares. Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, June 30th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 8th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Weiss Ratings lowered Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday. Finally, Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Fifteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $135.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source